Arch Biopartners Stock Fundamentals
| ACHFF Stock | USD 1.29 0.01 0.77% |
Arch Biopartners fundamentals help investors to digest information that contributes to Arch Biopartners' financial success or failures. It also enables traders to predict the movement of Arch OTC Stock. The fundamental analysis module provides a way to measure Arch Biopartners' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Arch Biopartners otc stock.
Arch |
Arch Biopartners OTC Stock Shares Outstanding Analysis
Arch Biopartners' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Arch Biopartners Shares Outstanding | 62.4 M |
Most of Arch Biopartners' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arch Biopartners is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Arch Biopartners has 62.4 M of shares currently outstending. This is 65.44% lower than that of the Healthcare sector and 41.6% lower than that of the Biotechnology industry. The shares outstanding for all United States stocks is 89.09% higher than that of the company.
Arch Biopartners Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Arch Biopartners's current stock value. Our valuation model uses many indicators to compare Arch Biopartners value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Arch Biopartners competition to find correlations between indicators driving Arch Biopartners's intrinsic value. More Info.Arch Biopartners is number one stock in return on asset category among related companies. It is number one stock in profit margin category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Arch Biopartners by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Arch Biopartners' OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Arch Biopartners' earnings, one of the primary drivers of an investment's value.Arch Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arch Biopartners' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Arch Biopartners could also be used in its relative valuation, which is a method of valuing Arch Biopartners by comparing valuation metrics of similar companies.Arch Biopartners is currently under evaluation in shares outstanding category among related companies.
Arch Fundamentals
| Return On Asset | -0.38 | |||
| Profit Margin | (1.46) % | |||
| Operating Margin | (1.03) % | |||
| Current Valuation | 136.63 M | |||
| Shares Outstanding | 62.4 M | |||
| Shares Owned By Insiders | 19.18 % | |||
| Price To Earning | 237.00 X | |||
| Price To Sales | 38.19 X | |||
| Gross Profit | (502.88 K) | |||
| EBITDA | (1.08 M) | |||
| Net Income | (1.39 M) | |||
| Cash And Equivalents | 585.57 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 2.31 M | |||
| Current Ratio | 0.75 X | |||
| Book Value Per Share | (0.07) X | |||
| Cash Flow From Operations | (2.98 M) | |||
| Earnings Per Share | 0.01 X | |||
| Target Price | 4.75 | |||
| Number Of Employees | 11 | |||
| Beta | 1.04 | |||
| Market Capitalization | 120.74 M | |||
| Total Asset | 621.64 K | |||
| Z Score | 27.9 | |||
| Net Asset | 621.64 K |
About Arch Biopartners Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arch Biopartners's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arch Biopartners using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arch Biopartners based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Arch Biopartners Inc., a biotechnology company, develops technologies for medical or commercial impact. In addition, it develops Borg, a peptide-solid surface interface to inhibit biofilm formation and reduce corrosion and MetaMx, which are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. Arch Biopartners is traded on OTC Exchange in the United States.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Arch Biopartners in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Arch Biopartners' short interest history, or implied volatility extrapolated from Arch Biopartners options trading.
Pair Trading with Arch Biopartners
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arch Biopartners position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arch Biopartners will appreciate offsetting losses from the drop in the long position's value.Moving against Arch OTC Stock
| 0.78 | DPSTF | Deutsche Post AG Earnings Call This Week | PairCorr |
| 0.71 | WXIBF | WuXi Biologics | PairCorr |
| 0.62 | VRTX | Vertex Pharmaceuticals Earnings Call This Week | PairCorr |
| 0.57 | ACN | Accenture plc Financial Report 27th of June 2024 | PairCorr |
| 0.46 | CSLLY | CSL | PairCorr |
The ability to find closely correlated positions to Arch Biopartners could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arch Biopartners when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arch Biopartners - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arch Biopartners to buy it.
The correlation of Arch Biopartners is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arch Biopartners moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arch Biopartners moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Arch Biopartners can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arch Biopartners. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in census. Note that the Arch Biopartners information on this page should be used as a complementary analysis to other Arch Biopartners' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Complementary Tools for Arch OTC Stock analysis
When running Arch Biopartners' price analysis, check to measure Arch Biopartners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arch Biopartners is operating at the current time. Most of Arch Biopartners' value examination focuses on studying past and present price action to predict the probability of Arch Biopartners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arch Biopartners' price. Additionally, you may evaluate how the addition of Arch Biopartners to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |